Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chair of the Department of Dermatology at Temple University School of Medicine (TUSM), and Director of the Temple Itch Center. The findings point to the involvement of the brain's opioid receptors—widely known for their roles in pain, reward, and addiction—in itch relief, potentially opening up new avenues to the development of treatments for chronic itch.
Misha Mutizwa, MD, has been appointed Assistant Professor of Dermatology at Temple University School of Medicine, and Director of HIV Dermatology at Temple University Hospital. He will also serve as Associate Director of the Dermatology Residency Program.
Dr. Mutizwa specializes in general dermatology and complex medical dermatology, with his primary clinical and research interests being HIV/AIDS-related dermatoses and inpatient dermatology. He will see patients at multiple sites within the Temple Health network.
Misha Mutizwa, MD, has been appointed Assistant Professor of Dermatology at Temple University School of Medicine, and Director of HIV Dermatology at Temple University Hospital. He will also serve as Associate Director of the Dermatology Residency Program.
Dr. Mutizwa specializes in general dermatology and complex medical dermatology, with his primary clinical and research interests being HIV/AIDS-related dermatoses and inpatient dermatology. He will see patients at multiple sites within the Temple Health network.
As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9 in the American Heart Association journal, Circulation.
Temple University School of Medicine (TUSM) has formalized a collaborative educational and research relationship with Taiwan’s Fu Jen Catholic University School of Medicine, the alma mater of TUSM benefactor and Temple University Board Member Dr. Solomon Luo.
Temple University Hospital is the only hospital in Philadelphia participating in an international clinical trial to evaluate the effectiveness of a device called a "stentriever" to remove brain-damaging clots that are causing a stroke. Patients began enrolling in the study at Temple on August 1.
Charles Munyon, MD, has been appointed Director of Functional and Restorative Neurosurgery at Temple University Hospital, and Assistant Professor of Neurosurgery at Temple University School of Medicine.
Dr. Munyon specializes in neuromodulation for movement disorders and chronic pain, as well as surgical evaluation and treatment of medically intractable epilepsy. His research interests include neuroprosthetics, brain/computer interface, and neuromodulation for psychiatric disorders.
I am deeply saddened to report that on Wednesday, August 13, the School of Medicine lost our dear friend, ambassador and trusted and valued administrator, Richard J. Kozera, MD, FACP, Executive Associate Dean. He was 74.
